At the same time, our results indicate that CX3CL1 can restore or enhance the anti-tumor activity of activated CD8+ T cells in the tumor immune microenvironment and, thereby, reshape the tumor immune microenvironment to improve the anti-tumor immunity of advanced ccRCC. Here, CD8A is linked to nonpapillary renal cell carcinoma.